Practice-changing data from the DESTINY-Breast04 study, presented during the 2022 Annual Meeting of the American Society of Clinical Oncology in Chicago, show that trastuzumab deruxtecan reduced the risk of disease progression or death by 50% compared with chemotherapy for human epidermal growth factor receptor-2 (HER2)–low patients with both hormone receptor (HR)–positive and HR-negative disease.
Read More
Abstracts Highlight Association Between Idiopathic Hypersomnia and Weight, Social Relationships
June 5th 2022Posters from the SLEEP 2022 conference revealed some of the interaction between idiopathic hypersomnia and different aspects of life, including weight changes and interpersonal relationships.
Read More
Dr David R. Penberthy: Knowledge Gained at ASCO Can Transform Cancer Care
June 5th 2022David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.
Watch
Study Identifies Predictors of Eosinophilic Disease in CRS With Nasal Polyps
June 4th 2022Asthma history and olfactory, rhinorrhea, and nasal polyp endoscopy scores were identified as independent predictors of eosinophilic disease in Chinese patients with chronic rhinosinusitis with nasal polyps.
Read More
Study: Suggested Cyclosporine Levels Posttransplant May Be Too Low to Prevent GVHD
June 4th 2022Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplant is a key aspect of patient management, but current cyclosporine concentration guidelines may not be sufficient, according to a recent study.
Read More
Dr Kashyap Patel Discusses the Importance of WES in Reducing Targeted Treatment Disparities
June 4th 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Watch
Dr Enrique Ocio Discusses the Advantages of Sub-Q Isatuximab for RRMM
June 4th 2022Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).
Watch
ASCO, WHO to Launch Global Quality Initiative in Cancer Care
June 4th 2022The collaboration, put in place through a Memorandum of Understanding, was presented Saturday in a keynote address by WHO Cancer Control Officer André Ilbawi, MD, during the presidential symposium at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago.
Read More
Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41%
June 4th 2022Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.
Read More
High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study
June 4th 2022As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
Read More
Dr Robert Sidbury Reviews Novel Topical, Systemic Therapies for Pediatric Atopic Dermatitis
June 3rd 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, provides an overview of recent approvals and indications under consideration for the treatment of pediatric atopic dermatitis.
Watch
Michael Hess Reviews Treatments for COPD and Assessing the Effectiveness of Therapies
June 3rd 2022Respiratory therapist Michael Hess, MPH, RRT, RPFT, discusses the main therapies used for chronic management of chronic obstructive pulmonary disorder (COPD), as well as the decision to escalate to triple therapy.
Read More
Sacubitril/Valsartan Reduces mPAP, Improves Functional Capacity in HFpEF-PH
June 3rd 2022Sacubitril/valsartan reduced mean pulmonary artery pressure (mPAP) and improved lung congestion, functional capacity, and quality of life in a subset of patients with heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH) using a remote monitoring platform.
Read More